Susan R. Kahn
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Susan R. Kahn
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Subsidiary | Pharmaceuticals: Major | 12 | |
National Tay-Sachs & Allied Diseases Association
National Tay-Sachs & Allied Diseases Association Miscellaneous Commercial ServicesCommercial Services National Tay-Sachs & Allied Diseases Association is a non-profit organization. The firm engages in the provision of funding, research, and support services for individual affected with Tay-Sachs, Canavan, Sandhoff, GM1 gangliosidosis, and related diseases. The company was founded in 1957 and is headquartered in Boston, MA.
1
| Non-Profit Organization | Miscellaneous Commercial Services | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Susan R. Kahn tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Director of Finance/CFO Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
VOYAGER THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO Founder | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor | |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Suffolk University | College/University | Undergraduate Degree | |
Judo Bio, Inc.
Judo Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Judo Bio, Inc. operates as a biotechnology company. The company is based in Cambridge, MA. The company was founded in 2021 by Chelsea Place Johnson. | Miscellaneous Commercial Services | Chairman | |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Undergraduate Degree | |
FATE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Medical/Nursing Services | Director/Board Member | |
SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal | |
Harvard Law School | College/University | Graduate Degree | |
IMMUNOGEN, INC. | Biotechnology | Chief Executive Officer | |
KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Director/Board Member | |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Biotechnology | Chairman | |
EVERCORE INC. | Investment Banks/Brokers | Corporate Officer/Principal | |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Biotechnology | Chief Executive Officer | |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member | |
SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer | |
VACCINEX, INC. | Biotechnology | Director/Board Member | |
Rochester Christian University | College/University | Doctorate Degree | |
LAGeT LLC
LAGeT LLC Electronic Equipment/InstrumentsElectronic Technology LAGeT LLC developed light activated gene transduction technology process which expands the utility of gene therapy vectors. It offered articular and meniscal cartilage repair, ligament and tendon healing and enhanced spinal fusion. The company was founded by Jeffrey J. Goater and Edward Schwarz and was headquartered in Rochester, NY. | Electronic Equipment/Instruments | Chief Executive Officer | |
Evercore Capital Partners
Evercore Capital Partners Investment ManagersFinance Evercore Capital Partners (Evercore Capital) is a private equity subsidiary of Evercore Group LLC founded in 1996 by Roger C. Altman. The firm is headquartered in New York. | Investment Managers | Corporate Officer/Principal | |
Cowen & Co. LLC
Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Investment Banks/Brokers | Analyst-Equity | |
COMPASS PATHWAYS PLC | Biotechnology | Director/Board Member | |
MINERALYS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director of Finance/CFO | |
American Cancer Society New England Division, Inc. | Director/Board Member | ||
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management LLC (Skyline Management) is a venture capital firm founded in 1997 by John Gordon Freund. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
ERGOMED | Miscellaneous Commercial Services | Director/Board Member | |
AGIOS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Emory University School of Medicine | College/University | Corporate Officer/Principal | |
Kdac Therapeutics, Inc. | Corporate Officer/Principal | ||
Vivid Biosciences LLC | Chief Tech/Sci/R&D Officer | ||
Cereius, Inc.
Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
University of Pennsylvania | College/University | Doctorate Degree | |
Tufts University | College/University | Undergraduate Degree | |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Corporate Officer/Principal | |
Genevant Sciences Corp.
Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Pharmaceuticals: Major | Director/Board Member | |
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Miscellaneous Commercial Services | Founder | |
Case Western Reserve University
Case Western Reserve University Other Consumer ServicesConsumer Services Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH. | College/University | Doctorate Degree | |
Michigan State University | College/University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 45 |
Regno Unito | 4 |
Irlanda | 2 |
Canada | 2 |
Settori
Health Technology | 24 |
Consumer Services | 12 |
Finance | 6 |
Commercial Services | 6 |
Health Services | 2 |
Posizioni
Director/Board Member | 58 |
Corporate Officer/Principal | 36 |
Independent Dir/Board Member | 27 |
Director of Finance/CFO | 22 |
Undergraduate Degree | 10 |
Contatti più connessi
Insiders | |
---|---|
Michael Wyzga | 31 |
Leon E. Chen | 19 |
J. Goater | 17 |
Daphne Karydas | 16 |
Mark Enyedy | 15 |
Joshua Blacher | 14 |
Richard A. Moscicki | 13 |
Mark A. Kay | 7 |
Mariana Nacht | 7 |
Jayne C. Gershkowitz | 6 |
Cecilia Jones | 5 |
Stephen Boyer | 4 |
Daniel J. Gruskin | 3 |
- Borsa valori
- Insiders
- Susan R. Kahn
- Connessioni Società